A buyout offer from Swedish Orphan Biovitrum drove up the stock's price.
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 54.55% and 5.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...
ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?